Pazopanib Shows Promising Results in Treating Children with Multi-Metastatic Ewing Sarcoma
核心洞察
A small retrospective study found that pazopanib, an anti-angiogenic drug, achieved an 85% two-year survival rate in children with multi-metastatic Ewing sarcoma (搜索), significantly higher than historical controls.
The drug was well-tolerated with minimal side effects and allowed for home-based treatment after initial IV therapy, improving quality of life for young patients.
Researchers from Warsaw Mother and Child Institute (搜索) call for larger controlled trials to validate these promising results in this rare but deadly pediatric bone cancer (搜索).
A small retrospective study has demonstrated promising results for pazopanib in treating children with multi-metastatic Ewing sarcoma (搜索), a rare but aggressive bone cancer (搜索) with historically poor outcomes. The research, conducted at the Warsaw Mother and Child Institute (搜索) between 2016 and 2024, found that 85% of patients survived two years after diagnosis when treated with pazopanib alongside standard therapies.
Addressing a Critical Unmet Need
Multi-metastatic Ewing sarcoma (搜索) presents a dire prognosis for pediatric patients, with some studies indicating that less than a quarter of children survive five years after diagnosis. Prof. Anna Raciborska, lead author of the study published in Frontiers in Oncology, described the survival rates as "dismal" for this patient population.
"Survival rates were higher than in historical controls, suggesting it may extend lives and, importantly, do so without adding severe toxicity," said Raciborska. "Moreover, the quality of life of treated children was good. After the end of IV treatment, patients could receive pazopanib as a home treatment."
Mechanism and Treatment Approach
Pazopanib, originally developed for renal cell carcinoma (搜索), works by blocking tumor angiogenesis (搜索)—the formation of new blood vessels (搜索) that tumors require for growth and metastasis. "Pazopanib is a pill that blocks the tumor's ability to grow new blood vessels, which tumors need to survive and spread," explained Raciborska. "By cutting off this 'blood supply', the drug presumably makes tumors weaker and more sensitive to chemotherapy and radiation."
The research team incorporated pazopanib into treatment regimens after observing success in adult Ewing sarcoma (搜索) patients, hypothesizing that combining it with standard therapies would target different aspects of the cancer simultaneously.
Study Results and Patient Outcomes
The non-randomized retrospective study included 11 patients aged five to 17 years who received pazopanib alongside standard first-line treatments. Patients took the drug for an average of 1.7 years, with treatment continuing during and after chemotherapy but paused for surgical procedures.
The comprehensive treatment approach included surgery for five children's primary tumors, stem cell transplants for three patients, and radiotherapy for 10 patients. Imaging studies revealed that all but one patient showed clear treatment response.
Key outcomes included:
- Two-year overall survival rate of 85.7%
- Event-free survival rate of 68.2% at two years
- 10 of 11 patients remained alive at the time of publication
- Six patients continued taking pazopanib at study completion
The drug demonstrated excellent tolerability with minimal, manageable side effects, addressing concerns about treatment toxicity in pediatric patients.
Clinical Implications and Future Directions
The results suggest pazopanib may be more effective and better tolerated in children compared to adult patients, potentially due to earlier intervention in the disease course. "While we wait for new treatment options, it is possible to implement this existing drug to improve outcomes in very high-risk patients," noted Raciborska. "It opens the door to targeted therapies earlier in the disease course, potentially improving survival and quality of life."
However, the researchers emphasize the need for larger validation studies. "While the results are encouraging, larger controlled trials are needed before changing standard practice," Raciborska cautioned. "Our study could serve as a basis for creating prospective, multicenter clinical trials to confirm these promising results."
The rarity of multi-metastatic Ewing sarcoma (搜索) presents challenges for conducting large-scale randomized trials, but the research team encourages the scientific community to further investigate pazopanib as a treatment option for children with severe metastases. The researchers hope future EU programs may provide the resources necessary for larger multicenter studies to validate these encouraging preliminary findings.